The role of adverse risk factors in response to epodyl treatment in superficial bladder cancer
暂无分享，去创建一个
A. West | J. Fitzpatrick | M. Butler | J. O'flynn | V. Lane
[1] W. Hop,et al. Single-dose intravesical Epodyl after TUR of Ta TCC bladder carcinoma , 1983, World Journal of Urology.
[2] P. Cangh,et al. Early adjuvant Adriamycin in superficial bladder carcinoma , 2004, Cancer Chemotherapy and Pharmacology.
[3] A B West,et al. Superficial bladder tumors (stage pTa, grades 1 and 2): the importance of recurrence pattern following initial resection. , 1986, The Journal of urology.
[4] J. Fitzpatrick,et al. Prognostic factors influencing survival of patients receiving intravesical epodyl. , 1982, The Journal of urology.
[5] J. Fitzpatrick,et al. Long-term follow-up in patients with superficial bladder tumours treated with intravesical Epodyl. , 1979, British journal of urology.
[6] J. Smith,et al. Epodyl in management of noninvasive vesical neoplasms. , 1978, Urology.
[7] M. Robinson,et al. Intravesical epodyl in the management of bladder tumors: combined experience of the Yorkshire Urological Cancer Research Group. , 1977, The Journal of urology.
[8] P. Riddle. The management of superficial bladder tumours with intravesical Epodyl. , 1973, British journal of urology.
[9] A. Abbassian,et al. Intracavitary chemotherapy of diffuse non-infiltrating papillary carcinoma of the bladder. , 1966, The Journal of urology.